AAHA issues first feline-only diabetes management guidelines: full analysis

AAHA has published its 2026 Diabetes Management Guidelines for Cats, a notable update that formally recognizes feline diabetes as its own clinical category rather than a variation on canine disease. The new document is the association’s first feline-only diabetes guideline, and it arrives as oral SGLT2 inhibitors, continuous glucose monitors, and new monitoring priorities are reshaping how many primary care teams approach diabetic cats. (aaha.org)

That split from prior guidance is a meaningful change in itself. AAHA’s earlier diabetes recommendations, last published in 2018 and later updated, covered both dogs and cats together. The 2026 feline guideline retains relevant material from that earlier document, but the task force says treatment strategies have diverged enough to justify separate recommendations. In particular, the emergence of SGLT2 inhibitors has created a different therapeutic pathway for cats than for dogs. AAHA Chief Medical Officer Jessica Vogelsang said the organization divided the guidelines into separate canine and feline documents because of the “unique nature of the disease process” in each species. (ebvminpractice.org)

The clinical details reflect that shift. According to AAHA, two SGLT2 inhibitors are now licensed in the United States for newly diagnosed, otherwise healthy diabetic cats that have not previously been treated with insulin: bexagliflozin and velagliflozin. The guideline’s Section 6 says these drugs are an appropriate option for a substantial proportion of patients, but only after thorough evaluation for comorbidities and ketosis risk. AAHA specifically highlights blood beta-hydroxybutyrate testing, careful screening, and clear stop-and-switch guidance if ketonuria develops. (ebvminpractice.org)

That caution is consistent with federal labeling and safety communications. FDA approved Bexacat, the first oral treatment for feline diabetes, in 2022, and later approved Senvelgo for similar use in certain cats. FDA says these drugs are not for cats previously treated with insulin, cats with insulin-dependent diabetes, or cats that are dehydrated, lethargic, poorly eating, or affected by diabetic ketoacidosis. The agency has also warned that cats treated with these products may face serious adverse reactions, including diabetic ketoacidosis and euglycemic diabetic ketoacidosis, and that regular blood and urine monitoring is essential. (fda.gov)

The guideline also updates how teams monitor diabetic cats. AAHA says continuous glucose monitoring has expanded access and utility, while in-hospital blood glucose curves are no longer recommended for cats because stress hyperglycemia and day-to-day variation can complicate interpretation. Instead, the document places more weight on home-based monitoring, clinical signs, and serial body weight, with the task force underscoring that a cat with stable or increasing weight and no clinical signs is likely well controlled. AAHA’s release also frames alleviating clinical signs as a meaningful treatment endpoint, rather than pursuing tight glycemic control at all costs. (aaha.org)

AAHA leaders are framing the document as a practical tool for general practice. In the association’s release, co-chair Renee Rucinsky said the separated feline and canine documents should make it easier for practitioners to go directly to the information they need, and called the updated SGLT2 content “invaluable.” The task force itself includes well-known internists and feline practitioners, with contributing reviewers from Kansas State and Auburn, which may help the guideline carry weight among clinicians deciding how quickly to revise protocols. (aaha.org)

Why it matters: For veterinary professionals, this is less about a headline-grabbing drug class than a workflow reset. The guideline gives primary care teams a framework for deciding which newly diagnosed cats may be candidates for oral therapy, which still need insulin-first management, how to monitor each group differently, and how to communicate realistic goals to pet parents. It also reinforces that convenience and quality of life can improve with oral options, but only when case selection is disciplined and follow-up is rigorous. In practice, that means more emphasis on intake screening, ketone testing, staff training, client education, and knowing when to escalate to emergency care or specialist consultation. (aaha.org)

What to watch: The next signal will be how quickly practices incorporate the algorithms into standard protocols, especially around SGLT2 candidate screening, CGM use, and recheck schedules, and whether AAHA’s forthcoming 2026 canine diabetes guideline sharpens the contrast even further. (aaha.org)